Los Angeles Capital Management LLC Acquires 67,740 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Los Angeles Capital Management LLC raised its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 83.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 148,490 shares of the biotechnology company's stock after acquiring an additional 67,740 shares during the period. Los Angeles Capital Management LLC owned approximately 0.06% of ADMA Biologics worth $2,968,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. USA Financial Formulas boosted its position in ADMA Biologics by 8.6% in the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock worth $136,000 after purchasing an additional 539 shares during the last quarter. Vontobel Holding Ltd. raised its stake in shares of ADMA Biologics by 7.0% in the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company's stock valued at $273,000 after buying an additional 888 shares during the period. Hollencrest Capital Management bought a new stake in shares of ADMA Biologics in the third quarter valued at $30,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of ADMA Biologics by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock valued at $163,000 after buying an additional 1,509 shares during the period. Finally, Quest Partners LLC bought a new stake in shares of ADMA Biologics in the second quarter valued at $29,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

Insider Buying and Selling

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the company's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares of the company's stock, valued at approximately $2,843,290.27. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the business's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares of the company's stock, valued at approximately $2,843,290.27. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of the firm's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock valued at $8,224,121 over the last 90 days. Company insiders own 3.70% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on ADMA shares. Raymond James boosted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th. Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, HC Wainwright upped their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, November 8th.

ADMA Biologics Trading Down 1.4 %

ADMA stock traded down $0.31 during trading on Wednesday, hitting $21.47. 2,435,199 shares of the company traded hands, compared to its average volume of 3,669,287. The firm has a market capitalization of $5.00 billion, a PE ratio of 76.68 and a beta of 0.64. ADMA Biologics, Inc. has a 1 year low of $3.60 and a 1 year high of $23.64. The company has a 50-day moving average of $18.42 and a 200-day moving average of $14.22. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same period in the prior year, the firm earned $0.01 EPS. Analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.